WO2001064243A3 - Utilisation de la proteine mic3 de toxoplasma gond11 en tant qu'agent immunogene - Google Patents

Utilisation de la proteine mic3 de toxoplasma gond11 en tant qu'agent immunogene Download PDF

Info

Publication number
WO2001064243A3
WO2001064243A3 PCT/FR2001/000514 FR0100514W WO0164243A3 WO 2001064243 A3 WO2001064243 A3 WO 2001064243A3 FR 0100514 W FR0100514 W FR 0100514W WO 0164243 A3 WO0164243 A3 WO 0164243A3
Authority
WO
WIPO (PCT)
Prior art keywords
toxoplasma gondii
immunogenic agent
mic3 protein
mic3
protein
Prior art date
Application number
PCT/FR2001/000514
Other languages
English (en)
Other versions
WO2001064243A2 (fr
Inventor
Maryse Lebrun
Daniel Bout
Original Assignee
Virsol
Maryse Lebrun
Daniel Bout
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virsol, Maryse Lebrun, Daniel Bout filed Critical Virsol
Priority to AU2001235740A priority Critical patent/AU2001235740A1/en
Publication of WO2001064243A2 publication Critical patent/WO2001064243A2/fr
Publication of WO2001064243A3 publication Critical patent/WO2001064243A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/45—Toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne l'utilisation de la protéine MIC3 de Toxoplasma gondii et/ou d'un de ses derivés en tant qu'agent immunogène ou en tant qu'antigène de vaccination.
PCT/FR2001/000514 2000-02-25 2001-02-22 Utilisation de la proteine mic3 de toxoplasma gond11 en tant qu'agent immunogene WO2001064243A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001235740A AU2001235740A1 (en) 2000-02-25 2001-02-22 Use of toxoplasma gondii mic3 protein and/or one of its derivatives as immunogenic agent or as vaccination antigen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0002390A FR2805466A1 (fr) 2000-02-25 2000-02-25 Utilisation de la proteine mic3 de toxoplasma gondii ou d'un de ses derives en tant qu'agent immunogene ou en tant qu'antigene de vaccination
FR00/02390 2000-02-25

Publications (2)

Publication Number Publication Date
WO2001064243A2 WO2001064243A2 (fr) 2001-09-07
WO2001064243A3 true WO2001064243A3 (fr) 2002-02-14

Family

ID=8847404

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/000514 WO2001064243A2 (fr) 2000-02-25 2001-02-22 Utilisation de la proteine mic3 de toxoplasma gond11 en tant qu'agent immunogene

Country Status (4)

Country Link
AR (1) AR027540A1 (fr)
AU (1) AU2001235740A1 (fr)
FR (1) FR2805466A1 (fr)
WO (1) WO2001064243A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2864966B1 (fr) * 2004-01-13 2006-05-05 Agronomique Inst Nat Rech Souches vaccinales d'apicomplexes de la famille des sarcocystidae.
MX2007009524A (es) 2005-03-08 2008-03-04 Kenton S R L Antigenos recombinantes quimericos de toxoplasma gondii.
CA3042718A1 (fr) * 2016-11-03 2018-05-11 Washington University Antigenes pour la detection d'une infection par toxoplasma par surveillance de l'immunite cellulaire

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061906A2 (fr) * 1998-05-28 1999-12-02 Abbott Laboratories Cocktails d'antigenes, antigene p35, et leurs applications

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061906A2 (fr) * 1998-05-28 1999-12-02 Abbott Laboratories Cocktails d'antigenes, antigene p35, et leurs applications

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ACHBAROU A ET AL: "Characterisation of microneme proteins of Toxoplasma gondii", MOLECULAR AND BIOCHEMICAL PARASITOLOGY, vol. 47, no. 2, 1991, pages 223 - 234, XP000960323 *
CHANNON J ET AL: "Attachment ligands of viable Toxoplasma gondii induce soluble immunosuppressive factors in human monocytes.", INFECTION AND IMMUNITY, vol. 67, no. 5, May 1999 (1999-05-01), pages 2547 - 2551, XP002152132 *
DUBREMETZ J-F ET AL: "Apical organelles and host-cell invasion by Apicomplexa", INTERNATIONAL JOURNAL FOR PARASITOLOGY, vol. 28, no. 7, July 1998 (1998-07-01), pages 1007 - 1013, XP000960321 *
DUBREMETZ J-F: "Host cell invasion by Toxoplasma gondii.", TRENDS IN MICROBIOLOGY, vol. 6, no. 1, January 1998 (1998-01-01), pages 27 - 30, XP000960333 *
GARCIA-REGUET N ET AL: "The microneme protein MIC3 of Toxoplasma gondii is a secretory adhesin that binds to both the surface of the host cells and th surface of the parasite", CELLULAR MICROBIOLOGY, vol. 2, no. 4, August 2000 (2000-08-01), pages 353 - 364, XP000960353 *
VELGE-ROUSSEL F ET AL: "Intranasal immunization with Toxoplasma gondii SAG1 induces protective cells into both NALT and GALT compartments.", INFECTION AND IMMUNITY, vol. 68, no. 2, February 2000 (2000-02-01), pages 969 - 972, XP002166703 *

Also Published As

Publication number Publication date
WO2001064243A2 (fr) 2001-09-07
AU2001235740A1 (en) 2001-09-12
AR027540A1 (es) 2003-04-02
FR2805466A1 (fr) 2001-08-31

Similar Documents

Publication Publication Date Title
WO2001070275A3 (fr) Conjugues de la camptothecine-acide polyglutamique et leurs procedes de preparation
AU2001255196A1 (en) Compositions and methods for enhancing immunogenicity of antigens
AU2001247535A1 (en) Soft tissue anchor
ZA200207589B (en) Multivalent antibodies and uses therefor. Multivalent antibodies and uses thereof.
WO2001034801A3 (fr) Vaccins contenant de la gelatine recombinante
WO2003051392A3 (fr) Vaccin
MXPA03007827A (es) Metodo y composicion para la coloracion permanente gradual de cabello.
AU2001241918A1 (en) Methods of enhancing activity of vaccines and vaccine compositions
AU2002221519A1 (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
HK1063726A1 (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
AU5577201A (en) Immunogenic pneumococcal protein and vaccine compositions thereof
WO2002036145A8 (fr) Kahalalide f
WO2002076485A3 (fr) Vaccin assurant la modulation entre des reponses immunitaires t1 et t2
AU2002368056A1 (en) Novel pla2 enzyme, it's antibody, enzyme inhibitor and use and the preparation methods thereof
AU2002365269A8 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
WO2001064243A3 (fr) Utilisation de la proteine mic3 de toxoplasma gond11 en tant qu'agent immunogene
MXPA03002875A (es) Composicion de vacuna y metodo de estabilizacion.
EP1032583A4 (fr) Immunisation active contre les antigenes associes a l'angiogenese
AU2002320079A1 (en) Vaccines, immunotherapeutics and methods of using the same
ZA200303826B (en) Immunoprotective recombinent antigen from Anaplasma marginale, vaccine compositions and methods of use.
AU2001261534A1 (en) The meca-79 antigen and related methods
AU2001297794A1 (en) Methods and compositions of human proteins and uses thereof.
ZA997265B (en) Leptospira vaccine antigens for the prevention of leptospirosis.
AU2001253469A1 (en) Compositions and methods for stabilizing modified tissue
AU2001231141A1 (en) Novel human septin and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP